Potential biomarkers of Poly (ADP-ribose) polymerase inhibitors for cancer therapy

As Olaparib has received FDA-approval for treatment of cancer patients with BRCA1 and BRCA2 mutations, the target related on Poly (ADP-ribose) polymerase (PARP) inhibitors have been emerging as a novel therapy for treatment of patients with advanced ovarian cancer. It has been observed that PARP inhibitors have optimistic antitumor activity of patients in advanced ovarian cancer bearing homologous recombination (HR) defects, supporting a substantially wider role for PARPi. Strategies to identify other potential biomarkers remain under investigation. Herein, we review recent updates on potential moleculars to predict biomarker of PARPi for cancer therapy and proposed an integrated biomarker system to predict the "appropriate users" of PARPi. It may help overcome PARPi treatment failure, which reveal novel insights into clinical use of PARPi.